This study evaluated the effect of different surgical interventions on sexual function in patients with benign prostatic obstruction (BPO). The authors concluded that the prostatic urethral lift (PUL) intervention provided significantly improved erectile function at 24 months.

This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with better PFS in these patients.

This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality.

This study investigated the effectiveness of RestoreX penile traction device in the treatment of penile complications after prostate surgery. Researchers suggested that RestoreX improves penis length and sexual function after prostate surgery. 

This study compared water vapor thermal therapy using the Rezum system and prostatic urethral lift (PUL) in the treatment of men with urinary symptoms from benign prostatic hyperplasia (BPH). Researchers suggested that both treatments improve symptoms and the quality of life of these patients. 

This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects.

This study aimed to evaluate the effectiveness of physical exercise in patients with prostate cancer. The study concluded that physical exercise is associated with reduction of tiredness, and improving functional capacity and quality of life in these patients.

This study reviewed the best phosphodiesterase type 5 inhibitors (PDE5is) for the treatment of erectile dysfunction (ED) after prostate surgery. Researchers suggested that avanafil (Spedra) might be the best PDE5i drug for these patients.

This review compared the outcomes of different combined therapy for erectile dysfunction (ED). Researchers suggested that a combination of phosphodiesterase 5 inhibitor (PDE5i) and antioxidants is safe and associated with improved outcomes in these patients. 

This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo.